These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 5481776)

  • 21. Plasma growth hormone and insulin response to levodopa and amantadine.
    Kytömäki O; Nousiainen R; Pekkarinen A; Rinne UK; Viljanen M
    J Neural Transm; 1973; 34(2):145-51. PubMed ID: 4722572
    [No Abstract]   [Full Text] [Related]  

  • 22. Blood levels of FSH, LH, TSH, and GH in parkinsonian patients before and during L-dopa treatment.
    Lundberg PO
    Acta Neurol Scand; 1972; 48(4):427-32. PubMed ID: 5072652
    [No Abstract]   [Full Text] [Related]  

  • 23. Defective release of growth hormone in parkinsonism improved by levodopa.
    Mena I; Cotzias GC; Brown FC; Papavasiliou PS; Miller ST
    N Engl J Med; 1973 Feb; 288(6):320-1. PubMed ID: 4682676
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of oral administration of L-dopa on plasma levels of TSH, ACTH and GH in normal subjects].
    Simonin R; Roux H; Oliver C; Jaquet P; Argemi B; Vague P
    Sem Hop; 1973 Feb; 49(9):617-21. PubMed ID: 4350369
    [No Abstract]   [Full Text] [Related]  

  • 25. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of dioxyphenylalanine (L-DOPA) on extrapyramidal motoric hyperkineses after prolonged neuroleptic therapy].
    Hippius H; Logemann G
    Arzneimittelforschung; 1970 Jul; 20(7):894-6. PubMed ID: 5536051
    [No Abstract]   [Full Text] [Related]  

  • 27. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 28. Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.
    Weintraub MI; Van Woert MH
    N Engl J Med; 1971 Feb; 284(8):412-5. PubMed ID: 5540479
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 31. Preliminary observations on L-dopa in the treatment of Parkinson's disease.
    Jelsma F; Roth R; Ross P; Davis J
    J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419
    [No Abstract]   [Full Text] [Related]  

  • 32. [Parkinsonism, vitiligo and L-dopa. Contribution to the study of the embryological and functional correlation between nervous system and skin].
    Iparraguirre CE
    Rev Neuropsiquiatr; 1971 Dec; 34(4):274-81. PubMed ID: 5164553
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of intravenous L-dopa on growth hormone and luteinizing hormone levels in man.
    Souvatzoglou A; von Werder K; Bottermann P
    Acta Endocrinol (Copenh); 1973 Jun; 73(2):259-65. PubMed ID: 4740825
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of L-dopa and chlorpromazine on human growth hormone and TSH secretion in normal subjects and acromegalics.
    Singh P; McDevitt DG; Mackay J; Hadden DR
    Horm Res; 1973; 4(5):293-301. PubMed ID: 4755420
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 37. [Changes of somatotropinemia in patients with acromegaly following administration of L-dopa].
    Chiodini PG; Liuzzi A; Cremascoli G; Botalla L
    Folia Endocrinol; 1973 Dec; 26(6):497-502. PubMed ID: 4801260
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
    [No Abstract]   [Full Text] [Related]  

  • 39. Some quantitative behavioral changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Geriatrics; 1972 Jun; 27(6):89-97. PubMed ID: 5032486
    [No Abstract]   [Full Text] [Related]  

  • 40. Mood changes during l-dopa therapy.
    Anumonye A
    J Med Soc N J; 1972 Feb; 69(2):139-43. PubMed ID: 4550284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.